



Press release from Emotra AB (publ)  
Göteborg, May 12, 2015

## Emotra's application for EU Horizon 2020 financial support

**Emotra has been notified by EU Horizon 2020 that we will not be granted the 50 KEUR financial support we had applied for in order to carry out a Phase 1 study. This Phase 1 study is a feasibility study to determine the possibility of expanding EDOR's indication range to also encompass children and adolescents up to the age of 20, as well as to investigate the requirements for developing "EDOR Interconnect", a global communication platform that would facilitate Emotra's communication with clinics around the world and help us service them.**

Emotra's application came close to being approved, but in the end did not succeed. The reviewers found that our description of the methodology for our research of the child and youth psychiatry market in Europe, as well as how we intend to generate high future revenue, was lacking. Furthermore, they stated that our description of the present competitive and market situation, and how a routine use of EDOR would improve this situation, were not sufficiently well laid out.

However, the reviewers did state that Emotra's application contained a very thorough description of the Company's own organisation, our resources in the form of competence and experience, the relevance of our network and our described strategy for implementing EDOR on the child and youth psychiatry market.

The Company's most important objective at the moment is to carry out the ongoing clinical multi-centre study on adults aged 18 and older. Since our ongoing study makes considerable workload demands in terms of monitoring and analysis of EDOR test data, the Board has decided that it would be better to complete this first study before we move on to expanding the indication range to children and youths under 20. Due to the fact that attempted suicide rates in these age groups continue to rise, we will carry out such a study in the future.

Based on the information on hand, the Board is convinced that it will be possible to update our application to amend these shortcomings with a limited effort. However, the Board has not yet decided if and when such a new EU application will be filed.

**For further information, please contact:** Claes Holmberg, CEO, telephone: +46 708 25 45 47, E-mail: [claes@emotra.se](mailto:claes@emotra.se)

---

*Emotra AB is listed on AktieTorget and the company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.*